一名患有罕见EGFR突变（S768I和V769L）的肺腺癌患者对阿法替尼的原发性耐药 - Suppr

Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.

作者信息

Niogret Julie, Coudert Bruno, Boidot Romain

机构信息

Department of Medical Oncology, Georges Francois Leclerc Cancer Center-UNICANCER, Dijon, France.

Platform of Transfer in Cancer Biology, Georges Francois Leclerc Cancer Center-UNICANCER, Dijon, France; GIMI Genetic and Immunology Medical Institute, Georges Francois Leclerc Cancer Center-UNICANCER, Dijon, France.

出版信息

J Thorac Oncol. 2018 Jul;13(7):e113. doi: 10.1016/j.jtho.2018.02.004.

DOI:10.1016/j.jtho.2018.02.004

PMID:29935845

Abstract

摘要

相似文献

Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.一名患有罕见EGFR突变（S768I和V769L）的肺腺癌患者对阿法替尼的原发性耐药

J Thorac Oncol. 2018 Jul;13(7):e113. doi: 10.1016/j.jtho.2018.02.004.

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.阿法替尼治疗伴有主要非常见表皮生长因子受体（EGFR）突变（G719X/L861Q/S768I）的未经治疗的 IIIB/IV 期肺腺癌：来自台湾的一项多中心观察性研究。

Target Oncol. 2023 Mar;18(2):195-207. doi: 10.1007/s11523-023-00946-w. Epub 2023 Feb 20.

Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.表皮生长因子受体（EGFR）第20外显子插入突变的肺腺癌患者对阿法替尼单药治疗的主要临床反应

Clin Lung Cancer. 2021 Jan;22(1):e112-e115. doi: 10.1016/j.cllc.2020.09.005. Epub 2020 Sep 18.

Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations.一名具有G719S和S768I双重表皮生长因子受体（EGFR）突变的肺腺癌患者的酪氨酸激酶抑制作用

J Thorac Oncol. 2018 Aug;13(8):e136-e137. doi: 10.1016/j.jtho.2018.03.021.

Afatinib Achieved Remarkable Disease Control in a Chinese Patient With Lung Adenocarcinoma Harboring Rare EGFR Exon 18-25 Kinase Domain Duplication.阿法替尼在一名患有罕见表皮生长因子受体（EGFR）外显子18 - 25激酶结构域重复的肺腺癌中国患者中实现了显著的疾病控制。

Am J Ther. 2020 Sep/Oct;27(5):e535-e537. doi: 10.1097/MJT.0000000000001005.

Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.在对阿法替尼和克唑替尼联合治疗敏感的肺腺癌中鉴定出一种与EGFR突变共存的新型MET外显子14跳跃变体

J Thorac Oncol. 2019 Apr;14(4):e70-e72. doi: 10.1016/j.jtho.2018.11.026.

An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.一例发生鳞状细胞癌转化的表皮生长因子受体（EGFR）突变型肺腺癌对阿法替尼表现出持久反应。

Intern Med. 2018 Dec 1;57(23):3429-3432. doi: 10.2169/internalmedicine.0999-18. Epub 2018 Aug 10.

Sunvozertinib overcoming resistance to afatinib and osimertinib in lung adenocarcinoma harboring an EGFR exon 18 DelE709_T710insD mutation.Sunvozertinib克服携带EGFR外显子18 DelE709_T710insD突变的肺腺癌对阿法替尼和奥希替尼的耐药性。

J Transl Med. 2024 Aug 14;22(1):761. doi: 10.1186/s12967-024-05522-y.

Responsiveness to Full-Dose Afatinib in a Patient With Lung Adenocarcinoma Harboring EGFR S768I and V769L Mutations.一名携带EGFR S768I和V769L突变的肺腺癌患者对全剂量阿法替尼的反应

J Thorac Oncol. 2019 Feb;14(2):e25-e27. doi: 10.1016/j.jtho.2018.10.165.

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.用递增剂量的阿法替尼建立并鉴定三种阿法替尼耐药的肺腺癌PC-9细胞系。

J Vis Exp. 2019 Jun 26(148). doi: 10.3791/59473.

引用本文的文献

High Incidence of False Positives in S768I Mutation Detection Using the Idylla qPCR System in Non-Small Cell Lung Cancer Patients.在非小细胞肺癌患者中使用Idylla qPCR系统检测S768I突变时假阳性发生率较高。

Diagnostics (Basel). 2025 Jan 30;15(3):321. doi: 10.3390/diagnostics15030321.

Structure-Guided Strategies of Targeted Therapies for Patients with -Mutant Non-Small Cell Lung Cancer.基于结构的 - 突变型非小细胞肺癌靶向治疗策略。

Biomolecules. 2023 Jan 20;13(2):210. doi: 10.3390/biom13020210.

Is There a Role for Large Exome Sequencing in the Management of Metastatic Non-Small Cell Lung Cancer: A Brief Report of Real Life.大外显子测序在转移性非小细胞肺癌管理中是否发挥作用：真实病例简短报告

Front Oncol. 2022 Mar 7;12:863057. doi: 10.3389/fonc.2022.863057. eCollection 2022.

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in -Mutant Lung Cancer.肿瘤分析揭示鳞状转化和脱靶改变是 - 突变肺癌一线奥希替尼耐药的早期机制。

Clin Cancer Res. 2020 Jun 1;26(11):2654-2663. doi: 10.1158/1078-0432.CCR-19-3563. Epub 2020 Jan 7.

Cryptotanshinone Suppresses Non-Small Cell Lung Cancer via microRNA-146a-5p/EGFR Axis.隐丹参酮通过 microRNA-146a-5p/EGFR 轴抑制非小细胞肺癌。

Int J Biol Sci. 2019 Apr 22;15(5):1072-1079. doi: 10.7150/ijbs.31277. eCollection 2019.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Primary Resistance to Afatinib in a Patient with Lung Adenocarcinoma Harboring Uncommon EGFR Mutations: S768I and V769L.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献